Aarti Drugs Limited share price
NSE: AARTIDRUGS · ISIN INE767A01016
Key numbers
- Market cap
- ₹ 3,901 Cr
- Current price
- ₹ 427.40
- 52-week high / low
- ₹ 534 / 319
- Stock P/E
- 20.4
- Book value
- ₹ 169.8
- Dividend yield
- 0.47%
- ROCE
- 11.9%
- ROE
- 13.4%
- Debt to equity
- 0.37
- Sales growth (3 yrs)
- -2.3%
- Profit growth (3 yrs)
- 5.4%
- 1-year return
- -17.4%
About Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, engages in the manufacture and marketing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzenesulphonyl chloride, benzenesulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene…
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 591 | 653 | 602 | 720 | 703 |
| Operating profit | 74 | 84 | 55 | 96 | 98 |
| Net profit | 54 | 45 | 41 | 55 | 50 |
| EPS (₹) | 5.91 | 4.95 | 4.44 | 6.05 | 5.49 |
Concall summary (2026-08-07)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- During Q1 FY27, our Sayakha facility continued its planned ramp-up and operated at nearly 65% utilization.
- Q1 FY27 revenue stood at INR703.6 crores compared to INR590.8 crores in Q1 FY26, reflecting a growth of 19% year-on-year.
Growth & demand
- EBITDA stood at INR96.9 crores versus INR74.4 crores in Q1 FY26, a growth of 30% year-on-year.
- PBT stood at INR69.2 crores as against INR51.1 crores, a growth of 35% year-on-year.
Margins & costs
- The industry also continued to witness elevated freight costs on certain routes , longer procurement cycles in a few regions, and increased volatility in raw material pricing.
- EBITDA margin stood at 13.8%, an expansion of 120 basis points year-on-year.
Capex & expansion
- Our brownfield expansion at the Baddi facility in the adjacent land parcel is progressing as planned.
- PBT margin stood at 9.9% an expansion of 120 basis points year-on-year.
Balance sheet & cash
- And Adhish, if you can just help understand, you're backward integrating in the product and it will obviously give some leverage as compared to the competition.
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.